Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Maher (London, United Kingdom), S. Stowasser (Ingelheim, Germany), Y. Nishioka (Tokushima, Japan), E. White (Ann Arbor, Michigan, United States of America), V. Cottin (Lyon, France), I. Noth (Chicago, Illinois, United States of America), M. Selman (Mexico City, Mexico), D. Wachtlin (Ingelheim, Germany), C. Diefenbach (Biberach an der Riss, Germany), R. Jenkins (Nottingham, United Kingdom). Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. 4804

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Outcomes for COPD pharmacological trials: from lung function to biomarkers Source: Eur Respir J 2008; 31: 416-469 Year: 2008 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Collagen degradation profile in serum of patients with COPD or IPF Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways Year: 2012 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients Source: International Congress 2016 – From microimaging to functional evaluation of the lung Year: 2016 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 The role of inflammatory biomarkers like precursors of COPD stability during long-term follow-up Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Differences in biomarkers of systemic inflammation in two phenotypes of COPD patients Source: Annual Congress 2011 - COPD: human studies Year: 2011 Assessment of blood biomarkers in patients with IPF under antifibrotic therapy Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Relationship between plasma amino acid levels and lung function decline in patients with COPD Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers Source: International Congress 2014 – Markers Year: 2014 Late Breaking Abstract - Repopulated healthy and IPF lung scaffolds show temporal differences in ECM turnover Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019